Comparative effectiveness review of antiplatelet agents in peripheral artery disease

Journal of the American Heart Association

Volumn 3, Issue 6, 2014, Pages

  Schmit, Kristine ^a,b   Dolor, Rowena J ^b,c   Schuyler Jones, W ^b   Vemulapalli, Sreekanth ^b   Hasselblad, Victor ^a   Subherwal, Sumeet ^b   Heidenfelder, Brooke ^c   Patel, Manesh R ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; PLACEBO; TICLOPIDINE;

ADULT; ANEMIA; ANKLE BRACHIAL INDEX; ARTERY REOCCLUSION; ARTICLE; ASYMPTOMATIC DISEASE; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIGESTIVE SYSTEM ULCER; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EPISTAXIS; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAZARD RATIO; HEALTH CARE SYSTEM; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMATOMA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELENA; MONOTHERAPY; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RASH; RESTENOSIS; RETINA HEMORRHAGE; RISK FACTOR; SECONDARY PREVENTION; SKIN BRUISING; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; SYSTEMATIC REVIEW; TOBACCO USE; VASCULAR PATENCY; WALKING DISTANCE; WALKING SPEED; ANALOGS AND DERIVATIVES; BLOOD; DRUG COMBINATION; PATIENT SAFETY; PERIPHERAL ARTERIAL DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME;

ASPIRIN; COMPARATIVE EFFECTIVENESS RESEARCH; DRUG THERAPY, COMBINATION; HUMANS; PATIENT SAFETY; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84939461445     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.113.001330     Document Type: Article

References (20)

1. IOM (Institute of Medicine). Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press; 2009. Available at: http://www.iom.edu/Reports/2009/ComparativeEffectivenessResearchPriorities. aspx. Accessed March 20, 2013.
2. Jones WS, Schmit KM, Vemulapalli S, Subherwal S, Patel MR, Hasselblad V, Heidenfelder BL, Chobot MM, Posey R, Wing L, Sanders GD, Dolor RJ. Treatment Strategies for Patients With Peripheral Artery Disease. Comparative Effectiveness Review No. 118. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No. 3-EHC089-EF. 2013. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed November 26, 2012.
3. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality. Available at: www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318. Accessed March 16, 2012.
4. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
5. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841-848.
6. Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007;261:276-284.
7. Mahmood A, Sintler M, Edwards AT, Smith SR, Simms MH, Vohra RK. The efficacy of aspirin in patients undergoing infra-inguinal bypass and identification of high risk patients. Int Angiol. 2003;22:302-307.
8. Horrocks M, Horrocks EH, Murphy P, Lane IF, Ruttley MS, Fligelstone LJ, Watson HR. The effects of platelet inhibitors on platelet uptake and restenosis after femoral angioplasty. Int Angiol. 1997;Jun;16(2):101-106.
9. Minar E, Ahmadi A, Koppensteiner R, Maca T, Stumpflen A, Ugurluoglu A, Ehringer H. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation. 1995;91:2167-2173.
10. Anonymous. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
11. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30:192-201.
12. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-1988.
13. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010;121:2575-2583.
14. Cassar K, Ford I, Greaves M, Bachoo P, Brittenden J. Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty. Br J Surg. 2005;92:159-165.
15. Belch JJ, Dormandy J, Biasi GM, Cairols M, Diehm C, Eikelboom B, Golledge J, Jawien A, Lepantalo M, Norgren L, Hiatt WR, Becquemin JP, Bergqvist D, Clement D, Baumgartner I, Minar E, Stonebridge P, Vermassen F, Matyas L, Leizorovicz A. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52:825-833, 833:e821-e822.
16. Tepe G, Bantleon R, Brechtel K, Schmehl J, Zeller T, Claussen CD, Strobl FF. Management of peripheral arterial interventions with mono or dual antiplatelet therapy-the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol. 2012;22:1998-2006.
17. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463-e654.
18. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a metaanalysis of randomized trials. JAMA. 2009;301:1909-1919.
19. Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev. 2011;11(11): CD001272. doi: 10.1002/14651858.CD001272.pub2.
20. Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA. Vorapaxar in patients with peripheral artery disease: results from TRA2 P-TIMI 50. Circulation. 2013;127:1522-1529.